IgA Nephropathy: A New Turning Point in Treatment

Recently, there's been a growing call to improve access to treatment for patients with severe, progressive IgA Nephropathy. This condition occurs when abnormal immune complexes deposit in the kidney glomeruli, causing chronic inflammation. It is most commonly diagnosed in young adults in their 20s and 30s. Initial symptoms include hematuria (blood in urine), proteinuria (protein in urine), and hypertension (high blood pressure), with a long-term risk of progressing to end-stage renal disease.

The Necessity of Treatment Development and Insurance Coverage

While targeted therapies for IgA Nephropathy have been developed, unfortunately, they are not covered by national health insurance, leaving many patients without access to treatment. Professor Yang Jae-won from Wonju Severance Christian Hospital pointed out, "Even with available medications, patients cannot receive treatment due to cost issues." In light of this situation, there are arguments for designating severe cases as a rare disease and applying special healthcare benefits (Sanjeong Teukrye).

The Importance of Patient Numbers and Treatment Criteria

Professor Yang estimates that there are approximately 9,700 patients with severe IgA Nephropathy. Current steroid treatments can cause various side effects, and many young women, in particular, abandon treatment due to changes in their appearance. Therefore, proteinuria is highlighted as a key indicator for assessing the severity and risk of progression. He emphasized the need for a treatment approach that considers proteinuria levels above 1.0g per day, along with kidney function.

Challenges and Solutions for Rare Disease Designation

Severe IgA Nephropathy has been nominated for rare disease status three times but has not yet been designated. This is partly due to the fact that the patient population is estimated to be under 20,000 and a lack of sufficient data to determine the level of medical aid required. However, the Korea Disease Control and Prevention Agency (KDCA) has stated that they could reconsider the designation if objective diagnostic criteria to distinguish severe cases and more comprehensive prevalence data are provided.

In conclusion, it is crucial to ensure that patients with IgA Nephropathy can receive better treatment. Despite the development of effective therapies, many patients miss out on treatment opportunities because they are not covered by insurance. Therefore, the government and relevant organizations must collaborate to resolve this issue. It is time for everyone to come together to bring a ray of hope to patients with severe IgA Nephropathy.